Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | FAAH | O00519 | 3/20 | 0.48 |
| ▸ | MGLL | Q99685 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | NQO1 | P15559 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1790282 | 0.89 | HTT (0.53) | KMT2ASMN1; SMN2USP2ESR2MAPT | |
| SCHEMBL1984815 | 0.83 | MGLL (0.53) | MEN1CYP2C19KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL7138089 | 0.81 | MEN1 (0.48) | MEN1CYP2C19KMT2ASMN1; SMN2USP2 | |
| SCHEMBL1787313 | 0.79 | ESR2 (0.59) | MEN1CYP2C19KMT2ASMN1; SMN2USP2 | |
| SCHEMBL12651582 | 0.79 | ALDH1A1 (0.58) | MEN1CYP2C19KMT2ASMN1; SMN2USP2 | |
| SCHEMBL1788257 | 0.78 | ESR2 (0.57) | MEN1CYP2C19KMT2ASMN1; SMN2USP2 | |
| SCHEMBL4764988 | 0.76 | NPC1 (0.59) | MEN1KMT2ASMN1; SMN2USP2ESR2 | |
| SCHEMBL7950858 | 0.76 | ALDH1A1 (0.55) | MEN1CYP2C19KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL14812959 | 0.75 | NR1H2 (0.66) | KMT2AESR2NR1H2NPC1RAB9A | |
| SCHEMBL1790023 | 0.75 | ESR2 (0.54) | ESR2NR1H2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | HRH4, HRH3, HRH2 | MEN1 2515/4885CYP2C19 342/4885KMT2A 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.